PL2880014T3 - Związki do leczenia chorób związanych ze szlakiem mTOR - Google Patents
Związki do leczenia chorób związanych ze szlakiem mTORInfo
- Publication number
- PL2880014T3 PL2880014T3 PL13827913T PL13827913T PL2880014T3 PL 2880014 T3 PL2880014 T3 PL 2880014T3 PL 13827913 T PL13827913 T PL 13827913T PL 13827913 T PL13827913 T PL 13827913T PL 2880014 T3 PL2880014 T3 PL 2880014T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- treatment
- related diseases
- mtor pathway
- pathway related
- Prior art date
Links
- 101150097381 Mtor gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/62—Carboxylic acid nitriles containing cyano groups and oxygen atoms being part of oxyimino groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012903365A AU2012903365A0 (en) | 2012-08-06 | Compounds for the treatment of mTOR pathway related diseases | |
| PCT/AU2013/000859 WO2014022879A1 (en) | 2012-08-06 | 2013-08-05 | Compounds for the treatment of mtor pathway related diseases |
| EP13827913.8A EP2880014B1 (en) | 2012-08-06 | 2013-08-05 | Compounds for the treatment of mtor pathway related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2880014T3 true PL2880014T3 (pl) | 2017-10-31 |
Family
ID=50067298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13827913T PL2880014T3 (pl) | 2012-08-06 | 2013-08-05 | Związki do leczenia chorób związanych ze szlakiem mTOR |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9790176B2 (pl) |
| EP (2) | EP2880014B1 (pl) |
| JP (2) | JP6441219B2 (pl) |
| KR (1) | KR102124392B1 (pl) |
| CN (2) | CN105496999A (pl) |
| AU (2) | AU2013302209B2 (pl) |
| CA (1) | CA2881325C (pl) |
| ES (2) | ES2627099T3 (pl) |
| NZ (2) | NZ631523A (pl) |
| PL (1) | PL2880014T3 (pl) |
| WO (1) | WO2014022879A1 (pl) |
| ZA (1) | ZA201501390B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2880014T3 (pl) * | 2012-08-06 | 2017-10-31 | Pitney Pharmaceuticals Pty Ltd | Związki do leczenia chorób związanych ze szlakiem mTOR |
| EP3062790B1 (en) * | 2013-11-01 | 2023-03-08 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
| US10258639B2 (en) * | 2014-05-06 | 2019-04-16 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy |
| WO2016137010A1 (en) * | 2015-02-24 | 2016-09-01 | Nihon Nohyaku Co., Ltd. | Anti cancer agent comprising aminoacetonitrile compound as active ingredient |
| SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| CA3111980A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3117336A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 |
| IL292612A (en) | 2019-11-01 | 2022-07-01 | Navitor Pharm Inc | Treatment methods using mtorc1 modulator |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| CN113577086B (zh) * | 2020-04-30 | 2023-05-02 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 |
| CA3183094A1 (en) * | 2020-05-11 | 2021-11-18 | Pitney Pharmaceuticals Pty Limited | Use of aminoacetonitrile compounds for the treatment of infection and disease |
| CN115304600B (zh) * | 2022-09-29 | 2023-01-13 | 北京鑫开元医药科技有限公司 | mTOR抑制剂、制备方法及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6239077B1 (en) | 1998-05-01 | 2001-05-29 | Nihon Nohyaku Co., Ltd. | Aminoacetonitrile derivative agricultural and horticultural insecticide containing the same and use thereof |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| RU2286775C2 (ru) * | 2000-12-20 | 2006-11-10 | Новартис Аг | Органические соединения |
| TW200628439A (en) * | 2004-11-09 | 2006-08-16 | Novartis Ag | Organic compounds |
| US20090286838A1 (en) * | 2004-12-06 | 2009-11-19 | Newsouth Innovations Pty Limited | Treatment for cancer |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| CN105534969B (zh) | 2012-03-23 | 2019-04-05 | 皮特尼制药股份有限公司 | 用于癌症治疗的激酶抑制剂 |
| PL2880014T3 (pl) | 2012-08-06 | 2017-10-31 | Pitney Pharmaceuticals Pty Ltd | Związki do leczenia chorób związanych ze szlakiem mTOR |
| EP3062790B1 (en) * | 2013-11-01 | 2023-03-08 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
-
2013
- 2013-08-05 PL PL13827913T patent/PL2880014T3/pl unknown
- 2013-08-05 WO PCT/AU2013/000859 patent/WO2014022879A1/en not_active Ceased
- 2013-08-05 CN CN201510883323.4A patent/CN105496999A/zh active Pending
- 2013-08-05 EP EP13827913.8A patent/EP2880014B1/en active Active
- 2013-08-05 ES ES13827913T patent/ES2627099T3/es active Active
- 2013-08-05 CN CN201380051602.3A patent/CN104837812B/zh active Active
- 2013-08-05 EP EP17162895.1A patent/EP3202397B1/en active Active
- 2013-08-05 US US14/420,081 patent/US9790176B2/en active Active
- 2013-08-05 JP JP2015525692A patent/JP6441219B2/ja active Active
- 2013-08-05 KR KR1020157003924A patent/KR102124392B1/ko active Active
- 2013-08-05 CA CA2881325A patent/CA2881325C/en active Active
- 2013-08-05 AU AU2013302209A patent/AU2013302209B2/en active Active
- 2013-08-05 NZ NZ631523A patent/NZ631523A/en unknown
- 2013-08-05 ES ES17162895T patent/ES2757598T3/es active Active
- 2013-08-05 NZ NZ729555A patent/NZ729555A/en not_active IP Right Cessation
-
2015
- 2015-03-02 ZA ZA2015/01390A patent/ZA201501390B/en unknown
-
2016
- 2016-09-28 AU AU2016234924A patent/AU2016234924B2/en not_active Ceased
-
2017
- 2017-06-05 US US15/613,635 patent/US10053422B2/en active Active
-
2018
- 2018-01-12 JP JP2018003249A patent/JP6509386B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1205502A1 (en) | 2015-12-18 |
| EP2880014A1 (en) | 2015-06-10 |
| JP6441219B2 (ja) | 2018-12-19 |
| US20170369435A1 (en) | 2017-12-28 |
| CN105496999A (zh) | 2016-04-20 |
| AU2016234924B2 (en) | 2017-04-13 |
| EP2880014B1 (en) | 2017-05-17 |
| JP2018062526A (ja) | 2018-04-19 |
| US9790176B2 (en) | 2017-10-17 |
| CA2881325C (en) | 2020-09-29 |
| JP6509386B2 (ja) | 2019-05-08 |
| AU2013302209B2 (en) | 2016-09-29 |
| ES2627099T3 (es) | 2017-07-26 |
| CN104837812A (zh) | 2015-08-12 |
| NZ729555A (en) | 2017-08-25 |
| AU2013302209A1 (en) | 2015-02-19 |
| JP2015524446A (ja) | 2015-08-24 |
| NZ631523A (en) | 2017-03-31 |
| EP3202397B1 (en) | 2019-09-25 |
| US20150166477A1 (en) | 2015-06-18 |
| ZA201501390B (en) | 2017-09-27 |
| CN104837812B (zh) | 2017-09-26 |
| EP2880014A4 (en) | 2015-12-30 |
| EP3202397A1 (en) | 2017-08-09 |
| KR20150081422A (ko) | 2015-07-14 |
| US10053422B2 (en) | 2018-08-21 |
| KR102124392B1 (ko) | 2020-06-19 |
| ES2757598T3 (es) | 2020-04-29 |
| AU2016234924A1 (en) | 2016-10-20 |
| WO2014022879A1 (en) | 2014-02-13 |
| CA2881325A1 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201402424B (en) | 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| ZA201501390B (en) | Compounds for the treatment of mtor pathway related diseases | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| HUE037600T2 (hu) | Vegyületek és készítmények paraziták által okozott fertõzések kezelésére | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| EP2994460A4 (en) | Compounds for treatment of angiogenesis-mediated diseases | |
| IL243637B (en) | PPAR-sparing compounds for the treatment of metabolic diseases | |
| IL239273A0 (en) | A method of treating diseases | |
| IL238592B (en) | Compounds for treatment of liver diseases | |
| IL275636A (en) | Medical combination for cancer treatment | |
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| IL236873A0 (en) | therapeutic compounds | |
| AU2012903365A0 (en) | Compounds for the treatment of mTOR pathway related diseases | |
| GB201207363D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201207359D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201207476D0 (en) | pharmaceutical for the treatment of leishmaniasis | |
| GB201106981D0 (en) | Compounds for the treatment of clostridium difficle-associated disease | |
| IL232294A0 (en) | Preparations for the treatment of diabetes | |
| GB201204645D0 (en) | Treatment of disease |